Guía para el diagnóstico y el tratamiento de la enfermedad de Ménière en Colombia
Barra lateral del artículo
Contenido principal del artículo
Resumen
Introducción: La enfermedad de Ménière es un trastorno crónico multifactorial del oído interno, caracterizado principalmente por vértigo, pérdida auditiva neurosensorial de baja a media frecuencia, tinnitus y plenitud aural, generalmente unilateral; su prevalencia oscila entre 17 y 513 casos por cada 100.000 personas, siendo más común en mujeres y en adultos mayores. La hipótesis central de la fisiopatología de la enfermedad de Méniére es el hidrops endolinfático; por su naturaleza impredecible y episódica de la afección y los ataques de vértigo graves e incapacitantes los pacientes sufren gran deterioro en su calidad de vida.
Descargas
Detalles del artículo
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
Este artículo es publicado por la Revista Acta de Otorrinolaringología & Cirugía de Cabeza y Cuello.
Este es un artículo de acceso abierto, distribuido bajo los términos de la LicenciaCreativeCommons Atribución-CompartirIgual 4.0 Internacional.( http://creativecommons.org/licenses/by-sa/4.0/), que permite el uso no comercial, distribución y reproducción en cualquier medio, siempre que la obra original sea debidamente citada.
eISSN: 2539-0856
ISSN: 0120-8411
Citas
De Ravin E, Quimby AE, Bartellas M, Swanson S, Hwa TP, Bigelow DC, et al. An Update on the Epidemiology and Clinicodemographic Features of Meniere’s Disease. Laryngoscope. 2024. doi: 10.1002/lary.31282
Bruderer SG, Bodmer D, Stohler NA, Jick SS, Meier CR. Population-Based Study on the Epidemiology of Ménière’s Disease. Audiol Neurootol. 2017;22(2):74-82. doi: 10.1159/000475875
Mirza S, Gokhale S. Pathophysiology of Meniere’s Disease. Up to Date on Meniere’s Disease. InTech; 2017. doi: 10.5772/66388
Ovalle AR, Machuca BM, Moreira Z. Pablo, Barría E. Tamara, Durán R. María, Osorio M. Jaime. Prevalencia de comorbilidad depresiva en la enfermedad de Ménière. Rev. Otorrinolaringol. Cir. Cabeza Cuello. 2021;81(2):175-180. doi: 10.4067/s0718- 48162021000200175.
Schmidt W, Sarran C, Ronan N, Barrett G, Whinney DJ, Fleming LE, et al. The Weather and Ménière’s Disease: A Longitudinal Analysis in the UK. Otol Neurotol. 2017;38(2):225-233. doi: 10.1097/MAO.0000000000001270
Hu C, Yang W, Kong W, Fan J, He G, Zheng Y, et al. Risk factors for Meniere disease: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2022;279(12):5485-5496. doi: 10.1007/s00405-022-07505-5
Jalil JM, Castro MC, Pérez DP, Sánchez D, Martínez D. Perfil clínico y poblacional de pacientes con vértigo.Clínica Occidente de Otorrinolaringología, Medellín, Colombia. Acta otorrinolaringol. cir. cabeza cuello. 2014;42(3):152-157.
Saeed SR. Fortnightly review. Diagnosis and treatment of Ménière’s disease. BMJ. 1998;316(7128):368-72. doi: 10.1136/ bmj.316.7128.368
Perez-Garrigues H, Lopez-Escamez JA, Perez P, Sanz R, Orts M, Marco J, et al. Time course of episodes of definitive vertigo in Meniere’s disease. Arch Otolaryngol Head Neck Surg. 2008;134(11):1149-54. doi: 10.1001/archotol.134.11.1149
Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandalà M, et al. Diagnostic criteria for Menière’s disease. J Vestib Res. 2015;25(1):1-7. doi: 10.3233/VES-150549 Acta de Otorrinolaringología & Cirugía de Cabeza y Cuello. 2024: 28-35 DOI.10.37076/acorl.v52i1.5394(2): 92-99 21
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi: 10.1177/0333102417738202
Brantberg K, Baloh RW. Similarity of vertigo attacks due to Meniere’s disease and benign recurrent vertigo, both with and without migraine. Acta Otolaryngol. 2011;131(7):722-7. doi: 10.3109/00016489.2011.556661
Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J, et al. Vestibular migraine: diagnostic criteria. J Vestib Res. 2012;22(4):167-72. doi: 10.3233/VES-2012-0453
Sharon JD, Trevino C, Schubert MC, Carey JP. Treatment of Menière’s Disease. Curr Treat Options Neurol. 2015;17(4):341. doi: 10.1007/s11940-015-0341-x
Léonard V, Garin P, Gilain C, Saerens M, Van Damme JP. Surgical labyrinthectomy in the treatment of unilateral Meniere disease: a Belgian retrospective study. Eur Arch Otorhinolaryngol. 2024;281(4):1753-1759. doi: 10.1007/s00405-023-08293-2
Luca P, Ralli M, Cassandro C, Russo FY, Gioacchini FM, Cavaliere M, et al. Surgical Management of Intractable Meniere’s Disease. Int Tinnitus J. 2022;26(1):50-56. doi: 10.5935/0946-5448.20220007
Zhang DG, Xu L, Han YC, Lyu YF, Luo JF, Li YW, et al. [Simultaneous triple semicircular canal plugging and cochlear implantation in advanced Meniere’s disease]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017;52(1):25-30. Chinese. doi: 10.3760/cma.j.i ssn.1673-0860.2017.01.005
van Sonsbeek S, Pullens B, van Benthem PP. Positive pressure therapy for Ménière’s disease or syndrome. Cochrane Database Syst Rev. 2015;2015(3):CD008419. doi: 10.1002/14651858.CD008419.pub2
Lempert T. Recurrent spontaneous attacks of dizziness. Continuum (Minneap Minn). 2012;18(5 Neuro-otology):1086-101. doi: 10.1212/01.CON.0000421620.10783.ac
Basura GJ, Adams ME, Monfared A, Schwartz SR, Antonelli PJ, Burkard R, et al. Clinical Practice Guideline: Ménière’s Disease. Otolaryngol Head Neck Surg. 2020;162(2_suppl):S1-S55. doi: 10.1177/0194599820909438
Gizzi M, Riley E, Molinari S. The diagnostic value of imaging the patient with dizziness. A Bayesian approach. Arch Neurol. 1996;53(12):1299-304. doi: 10.1001/archneur.1996.00550120111024
Ahsan SF, Standring R, Osborn DA, Peterson E, Seidman M, Jain R. Clinical predictors of abnormal magnetic resonance imaging findings in patients with asymmetric sensorineural hearing loss. JAMA Otolaryngol Head Neck Surg. 2015;141(5):451-6. doi: 10.1001/jamaoto.2015.142
Margolis RH, Saly GL. Asymmetric hearing loss: definition, validation, and prevalence. Otol Neurotol. 2008;29(4):422-31. doi: 10.1097/MAO.0b013e31816c7c09
Agrawal Y, Platz EA, Niparko JK. Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and Nutrition Examination Survey, 1999-2004. Arch Intern Med. 2008;168(14):1522-30. doi: 10.1001/ archinte.168.14.1522
Chia EM, Wang JJ, Rochtchina E, Cumming RR, Newall P, Mitchell P. Hearing impairment and health-related quality of life: the Blue Mountains Hearing Study. Ear Hear. 2007;28(2):187-95. doi: 10.1097/AUD.0b013e31803126b6
Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol. 2009;4(2):461-9. doi: 10.2215/CJN.06011108
Crowson MG, Rocke DJ, Hoang JK, Weissman JL, Kaylie DM. Cost-effectiveness analysis of a non-contrast screening MRI protocol for vestibular schwannoma in patients with asymmetric sensorineural hearing loss. Neuroradiology. 2017;59(8):727-736. doi: 10.1007/s00234-017-1859-2
Daniels RL, Shelton C, Harnsberger HR. Ultra high resolution nonenhanced fast spin echo magnetic resonance imaging: cost-effective screening for acoustic neuroma in patients with sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 1998;119(4):364-9. doi: 10.1016/S0194-5998(98)70080-4
Daniels RL, Swallow C, Shelton C, Davidson HC, Krejci CS, Harnsberger HR. Causes of unilateral sensorineural hearing loss screened by high-resolution fast spin echo magnetic resonance imaging: review of 1,070 consecutive cases. Am J Otol. 2000;21(2):173-80. doi: 10.1016/s0196-0709(00)80005-8
Hentschel MA, Kunst HPM, Rovers MM, Steens SCA. Diagnostic accuracy of high-resolution T2-weighted MRI vs contrast-enhanced T1-weighted MRI to screen for cerebellopontine angle lesions in symptomatic patients. Clin Otolaryngol. 2018;43(3):805-811. doi: 10.1111/coa.13051
Sedwick JD, Gajewski BJ, Prevatt AR, Antonelli PJ. Magnetic resonance imaging in the search for retrocochlear pathology. Otolaryngol Head Neck Surg. 2001;124(6):652-5. doi: 10.1177/019459980112400610
Goebel JA. 2015 Equilibrium Committee Amendment to the 1995 AAO-HNS Guidelines for the Definition of Ménière’s Disease. Otolaryngol Head Neck Surg. 2016;154(3):403-4. doi: 10.1177/0194599816628524
Taylor RL, Wijewardene AA, Gibson WP, Black DA, Halmagyi GM, Welgampola MS. The vestibular evoked-potential profile of Ménière’s disease. Clin Neurophysiol. 2011;122(6):1256-63. doi: 10.1016/j.clinph.2010.11.009
Arnold W, Altermatt HJ, Gebbers JO, Laissue J. Secretory immunoglobulin A in the human endolymphatic sac. An immunohistochemical study. ORL J Otorhinolaryngol Relat Spec. 1984;46(6):286-8. doi: 10.1159/000275725
Sziklai I, Ferrary E, Horner KC, Sterkers O, Amiel C. Time-related alteration of endolymph composition in an experimental model of endolymphatic hydrops. Laryngoscope. 1992;102(4):431-8. doi: 10.1288/00005537-199204000-00011
Morrison AW, Johnson KJ. Genetics (molecular biology) and Meniere’s disease. Otolaryngol Clin North Am. 2002;35(3):497-516. doi: 10.1016/s0030-6665(02)00018-x
Salt AN, DeMott JE. Ionic and potential changes of the endolymphatic sac induced by endolymph volume changes. Hear Res. 2000;149(1-2):46-54. doi: 10.1016/s0378-5955(00)00160-x
Vrabec JT. Herpes simplex virus and Meniere’s disease. Laryngoscope. 2003;113(9):1431-8. doi: 10.1097/00005537-200309000- 00002
Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandalà M, et al. Criterios diagnósticos de enfermedad de Menière. Documento de consenso de la Bárány Society, la Japan Society for Equilibrium Research, la European Academy of Otology and Neurotology (EAONO), la American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) y la Korean Balance Society [Diagnostic criteria for Menière’s disease. Consensus document of the Bárány Society, the Japan Society for Equilibrium 22 Prieto-Rivera JA, Sánchez-Villegas E, Porras-Martínez MH. Research, the European Academy of Otology and Neurotology (EAONO), the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and the Korean Balance Society]. Acta Otorrinolaringol Esp. 2016;67(1):1-7. Spanish. doi: 10.1016/j. otorri.2015.05.005
Paparella MM. Pathology of Meniere’s disease. Ann Otol Rhinol Laryngol Suppl. 1984;112:31-5. doi: 10.1177/00034894840930s406
Kelly EA, Stocker C, Kempton CM, Dierking DM, Fehlberg HE, Adams ME. Vestibular Testing: Patient Perceptions, Morbidity, and Opportunity Costs. Otol Neurotol. 2018;39(10):1222-1228. doi: 10.1097/MAO.0000000000002025
Furstenberg AC, Lashmet FH, Lathrop F. Meniere’s symptom complex: medical treatment. 1934. Ann Otol Rhinol Laryngol. 1992;101(1):20-31. doi: 10.1177/000348949210100109
Schenck AA, Bommeljé CC, van Benthem PPG, Blom HM. Quality of life after intratympanic steroid injection for Ménière’s disease. Laryngoscope Investig Otolaryngol. 2022;7(3):825-831. doi: 10.1002/lio2.798
Trune DR, Kempton JB, Gross ND. Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. Hear Res. 2006;212(1-2):22-32. doi: 10.1016/j.heares.2005.10.006
Pondugula SR, Sanneman JD, Wangemann P, Milhaud PG, Marcus DC. Glucocorticoids stimulate cation absorption by semicircular canal duct epithelium via epithelial sodium channel. Am J Physiol Renal Physiol. 2004;286(6):F1127-35. doi: 10.1152/ ajprenal.00387.2003
Otake H, Yamamoto H, Teranishi M, Sone M, Nakashima T. Cochlear blood flow during occlusion and reperfusion of the anterior inferior cerebellar artery--effect of topical application of dexamethasone to the round window. Acta Otolaryngol. 2009;129(2):127-31. doi: 10.1080/00016480802078119
Kim SH, Marcus DC. Regulation of sodium transport in the inner ear. Hear Res. 2011;280(1-2):21-9. doi: 10.1016/j.heares.2011.05.003
El Shafei RR, Qotb M. Comparison of the effect Of three treatment interventions for the control of Meniere’s disease: a randomized control trial. Egypt J Otolaryngol. 2020;36(1). doi: 10.1186/s43163-020-00018-0
Garduño-Anaya MA, Couthino De Toledo H, Hinojosa-González R, Pane-Pianese C, Ríos-Castañeda LC. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière’s disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg. 2005;133(2):285-94. doi: 10.1016/j.otohns.2005.05.010
Thorp MA, Shehab ZP, Bance ML, Rutka JA; AAO-HNS Committee on Hearing and Equilibrium. The AAO-HNS Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière’s disease: have they been applied in the published literature of the last decade? Clin Otolaryngol Allied Sci. 2003;28(3):173-6. doi: 10.1046/j.1365-2273.2003.00687.x
Sarafraz M, Saki N, Nikakhlagh S, Mashali L, Arad A. Comparison the Efficacy of Intratympanic Injections of Methylprednisolone and Gentamicin to Control Vertigo in Unilateral Meniere’s Disease. BPJ. 2015;8(october Spl Edition):705–9. doi:10.13005/bpj/772
Patel M, Agarwal K, Arshad Q, Hariri M, Rea P, Seemungal BM, Golding JF, Harcourt JP, Bronstein AM. Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière’s disease: a randomised, double-blind, comparative effectiveness trial. Lancet. 2016;388(10061):2753-2762. doi: 10.1016/S0140-6736(16)31461-1
Casani AP, Piaggi P, Cerchiai N, Seccia V, Franceschini SS, Dallan I. Intratympanic treatment of intractable unilateral Meniere disease: gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol Head Neck Surg. 2012;146(3):430-7. doi: 10.1177/0194599811429432
ElBeltagy YF, Shafik AG, Mahmoud AM, Hazaa NM. Intratympanic injection in Meniere’s disease; symptomatic and audiovestibular; comparative, prospective randomized 1-year control study. Egypt J Otolaryngol. 2012;28(3):171–83. doi: 10.7123/01. EJO.0000418018.88180.0c
Phillips JS, Westerberg B. Intratympanic steroids for Ménière’s disease or syndrome. Cochrane Database Syst Rev. 2011;(7):CD008514. doi: 10.1002/14651858.CD008514.pub2
Paragache G, Panda NK, Ragunathan M, Sridhara. Intratympanic dexamethasone application in Meniere’s disease-Is it superior to conventional therapy? Indian J Otolaryngol Head Neck Surg. 2005;57(1):21-3. doi: 10.1007/BF02907620
Patel M. Intratympanic corticosteroids in Ménière’s disease: A mini-review. J Otol. 2017;12(3):117-124. doi: 10.1016/j.joto.2017.06.002
Lavigne P, Lavigne F, Saliba I. Intratympanic corticosteroids injections: a systematic review of literature. Eur Arch Otorhinolaryngol. 2016;273(9):2271-8. doi: 10.1007/s00405-015-3689-3
Syed MI, Ilan O, Nassar J, Rutka JA. Intratympanic therapy in Meniere’s syndrome or disease: up to date evidence for clinical practice. Clin Otolaryngol. 2015;40(6):682-90. doi: 10.1111/coa.12449
Doyle KJ, Bauch C, Battista R, Beatty C, Hughes GB, Mason J, et al. Intratympanic steroid treatment: a review. Otol Neurotol. 2004;25(6):1034-9. doi: 10.1097/00129492-200411000-00031
Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, Schwartz SR, Barrs DM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012;146(3 Suppl):S1-35. doi: 10.1177/0194599812436449
Lambert PR, Carey J, Mikulec AA, LeBel C; Otonomy Menières Study Group. Intratympanic Sustained-Exposure Dexamethasone Thermosensitive Gel for Symptoms of Menières Disease: Randomized Phase 2b Safety and Efficacy Trial. Otol Neurotol. 2016;37(10):1669-1676. doi: 10.1097/MAO.0000000000001227
Lambert PR, Nguyen S, Maxwell KS, Tucci DL, Lustig LR, Fletcher M, et al. A randomized, double-blind, placebo-controlled clinical study to assess safety and clinical activity of OTO-104 given as a single intratympanic injection in patients with unilateral Ménière’s disease. Otol Neurotol. 2012;33(7):1257-65. doi: 10.1097/MAO.0b013e318263d35d
Clinical Trials.gov [Internet]. A 6-month, prospective, randomized, multicenter, placebo-controlled safety study of OTO-104 given at 3-month intervals by intratympanic injection in subjects with unilateral Meniere’s disease followed by a 6-month open-label extension (NCT02265393). [Recibido el 15 de octubre de 2014]. Disponible en: https://clinicaltrials.gov/ct2/show/ NCT02265393
European Union Clinical Trials Register [Internet]. A prospective, randomized, double-blind, placebo-controlled, multicentre, phase 3 efficacy and safety study of OTO-104 given as a single intratympanic injection in subjects with unilateral Ménière’s disease. Disponible en: https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001464-35/ES
Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC. Otolaryngol Head Neck Surg. 1995;113(3):179-80. doi: 10.1016/S0194-5998(95)70101-X Acta de Otorrinolaringología & Cirugía de Cabeza y Cuello. 2024: 28-35 DOI.10.37076/acorl.v52i1.5394(2): 92-99 23
Huon LK, Fang TY, Wang PC. Outcomes of intratympanic gentamicin injection to treat Ménière’s disease. Otol Neurotol. 2012;33(5):706-14. doi: 10.1097/MAO.0b013e318259b3b1
Bremer HG, van Rooy I, Pullens B, Colijn C, Stegeman I, van der Zaag-Loonen HJ, et al. Intratympanic gentamicin treatment for Ménière’s disease: a randomized, double-blind, placebo-controlled trial on dose efficacy - results of a prematurely ended study. Trials. 2014;15:328. doi: 10.1186/1745-6215-15-328
Postema RJ, Kingma CM, Wit HP, Albers FW, Van Der Laan BF. Intratympanic gentamicin therapy for control of vertigo in unilateral Menire’s disease: a prospective, double-blind, randomized, placebo-controlled trial. Acta Otolaryngol. 2008;128(8):876-80. doi: 10.1080/00016480701762458
Choudhary A, Biswas K Das, Basak B, Ghosh SK, Bhattacharya D. Intratympanic Low Dose Gentamicin In Intractable Meniere’s Disease- Chemical Labyrinthectomy Revisited. J Evol Med Dent Sci. 2019;8(23):1843–7. doi: 10.14260/jemds/2019/405
Stokroos R, Kingma H. Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Menières disease: a prospective, double-blind, placebo-controlled, randomized clinical trial. Acta Otolaryngol. 2004;124(2):172-5. doi: 10.1080/00016480410016621
Chia SH, Gamst AC, Anderson JP, Harris JP. Intratympanic gentamicin therapy for Menières disease: a meta-analysis. Otol Neurotol. 2004;25(4):544-52. doi: 10.1097/00129492-200407000-00023
Webster KE, Galbraith K, Lee A, Harrington-Benton NA, Judd O, Kaski D, et al. Intratympanic gentamicin for Menières disease. Cochrane Database Syst Rev. 2023;2(2):CD015246. doi: 10.1002/14651858.CD015246.pub2
Yetiser S. Intratympanic Gentamicin for Intractable Menières Disease - A Review and Analysis of Audiovestibular Impact. Int Arch Otorhinolaryngol. 2018;22(2):190-194. doi: 10.1055/s-0037-1604064
Lindsay JR. Labyrinthine surgery for Menières disease. Laryngoscope. 1949;59(1):22-34. doi: 10.1288/00005537-194901000-00003
Diaz RC, LaRouere MJ, Bojrab DI, Zappia JJ, Sargent EW, Shaia WT. Quality-of-life assessment of Ménières disease patients after surgical labyrinthectomy. Otol Neurotol. 2007;28(1):74-86. doi: 10.1097/01.mao.0000233815.71671.6c
Kemink JL, Telian SA, Graham MD, Joynt L. Transmastoid labyrinthectomy: reliable surgical management of vertigo. Otolaryngol Head Neck Surg. 1989;101(1):5-10. doi: 10.1177/019459988910100102
Langman AW, Lindeman RC. Surgery for vertigo in the nonserviceable hearing ear: transmastoid labyrinthectomy or translabyrinthine vestibular nerve section. Laryngoscope. 1993;103(12):1321-5. doi: 10.1288/00005537-199312000-00001
Ghossaini SN, Wazen JJ. An update on the surgical treatment of Ménières diseases. J Am Acad Audiol. 2006;17(1):38-44. doi: 10.3766/jaaa.17.1.5
Hansen MR, Gantz BJ, Dunn C. Outcomes after cochlear implantation for patients with single-sided deafness, including those with recalcitrant Ménière’s disease. Otol Neurotol. 2013;34(9):1681-7. doi: 10.1097/MAO.0000000000000102
Doobe G, Ernst A, Ramalingam R, Mittmann P, Todt I. Simultaneous Labyrinthectomy and Cochlear Implantation for Patients with Single-Sided Ménière’s Disease and Profound Sensorineural Hearing Loss. Biomed Res Int. 2015;2015:457318. doi: 10.1155/2015/457318
Nevoux J, Barbara M, Dornhoffer J, Gibson W, Kitahara T, Darrouzet V. International consensus (ICON) on treatment of Ménière’s disease. Eur Ann Otorhinolaryngol Head Neck Dis. 2018;135(1S):S29-S32. doi: 10.1016/j.anorl.2017.12.006
Alarcón AV, Hidalgo LO, Arévalo RJ, Diaz MP. Labyrinthectomy and Vestibular Neurectomy for Intractable Vertiginous Symptoms. Int Arch Otorhinolaryngol. 2017;21(2):184-190. doi: 10.1055/s-0037-1599242
Goksu N, Yilmaz M, Bayramoglu I, Bayazit YA. Combined retrosigmoid retrolabyrinthine vestibular nerve section: results of our experience over 10 years. Otol Neurotol. 2005;26(3):481-3. doi: 10.1097/01.mao.0000169778.54162.7d
Glasscock ME 3rd, Thedinger BA, Cueva RA, Jackson CG. An analysis of the retrolabyrinthine vs. the retrosigmoid vestibular nerve section. Otolaryngol Head Neck Surg. 1991;104(1):88-95. doi: 10.1177/019459989110400116
Syed MI, Ilan O, Leong AC, Pothier DD, Rutka JA. Ménière’s Syndrome or Disease: Time Trends in Management and Quality of Evidence Over the Last Two Decades. Otol Neurotol. 2015;36(8):1309-16. doi: 10.1097/MAO.0000000000000831
House WF. Subarachnoid shunt for drainage of endolymphatic hydrops. A preliminary report. Laryngoscope. 1962;72:713-29. doi: 10.1288/00005537-196206000-00003
Gianoli GJ, Larouere MJ, Kartush JM, Wayman J. Sac-vein decompression for intractable Meniere’s disease: two-year treatment results. Otolaryngol Head Neck Surg. 1998;118(1):22-9. doi: 10.1016/S0194-5998(98)70370-5
Shambaugh GE Jr, Clemis JD, Arenberg IK. Endolymphatic duct and sac in Meniere’s disease. Arch Otolaryngol. 1969;89(6):816-25. doi: 10.1001/archotol.1969.00770020818006
Bretlau P, Thomsen J, Tos M, Johnsen NJ. Placebo effect in surgery for Menière’s disease. A double-blind placebo-controlled study on endolymphatic sac shunt surgery. Adv Otorhinolaryngol. 1982;28:139-46.
Bretlau P, Thomsen J, Tos M, Johnsen NJ. Placebo effect in surgery for Meniere’s disease: a three-year follow-up study of patients in a double blind placebo controlled study on endolymphatic sac shunt surgery. Am J Otol. 1984;5(6):558-61.
Thomsen J, Bretlau P, Tos M, Johnsen NJ. Ménière’s disease: endolymphatic sac decompression compared with sham (placebo) decompression. Ann N Y Acad Sci. 1981;374:820-30. doi: 10.1111/j.1749-6632.1981.tb30922.x
Thomsen J, Bretlau P, Tos M, Johnsen NJ. Placebo effect in surgery for Ménière’s disease. A double-blind, placebo-controlled study on endolymphatic sac shunt surgery. Arch Otolaryngol. 1981;107(5):271-7. doi: 10.1001/archotol.1981.00790410009002
Welling DB, Nagaraja HN. Endolymphatic mastoid shunt: a reevaluation of efficacy. Otolaryngol Head Neck Surg. 2000;122(3):340- 5. doi: 10.1016/S0194-5998(00)70044-1
Telischi FF, Luxford WM. Long-term efficacy of endolymphatic sac surgery for vertigo in Menière’s disease. Otolaryngol Head Neck Surg. 1993;109(1):83-7. doi: 10.1177/019459989310900115
Brinson GM, Chen DA, Arriaga MA. Endolymphatic mastoid shunt versus endolymphatic sac decompression for Ménière’s disease. Otolaryngol Head Neck Surg. 2007;136(3):415-21. doi: 10.1016/j.otohns.2006.08.031
Brackmann DE, Nissen RL. Menière’s disease: results of treatment with the endolymphatic subarachnoid shunt compared with the endolymphatic mastoid shunt. Am J Otol. 1987;8(4):275-82.
Brackmann DE, Anderson RG. Ménière’s disease: results of treatment with the endolymphatic subarachnoid shunt. ORL J Otorhinolaryngol Relat Spec. 1980;42(1-2):101-18. doi: 10.1159/000275481
Paparella MM, Sajjadi H. Endolymphatic sac enhancement. Principles of diagnosis and treatment. Am J Otol. 1987;8(4):294-300.
Welsh LW, Welsh JJ, Rosen LF, Dragonette JE. Functional impairments due to unilateral deafness. Ann Otol Rhinol Laryngol. 2004;113(12):987-93. doi: 10.1177/000348940411301209
Moeller MP, McCleary E, Putman C, Tyler-Krings A, Hoover B, Stelmachowicz P. Longitudinal development of phonology and morphology in children with late-identified mild-moderate sensorineural hearing loss. Ear Hear. 2010;31(5):625-35. doi: 10.1097/ AUD.0b013e3181df5cc2 24 Prieto-Rivera JA, Sánchez-Villegas E, Porras-Martínez MH.
Huppert D, Strupp M, Brandt T. Long-term course of Menière’s disease revisited. Acta Otolaryngol. 2010;130(6):644-51. doi: 10.3109/00016480903382808
McNeill C, McMahon CM, Newall P, Kalantzis M. Hearing aids for Ménière’s syndrome: implications of hearing fluctuation. J Am Acad Audiol. 2008;19(5):430-4. doi: 10.3766/jaaa.19.5.5
National Institutes of Health (NIH) [Internet]. National Institute on Deafness and Other Communication Disorders (NIDCD). [Citado el 11 de abril de 2024]. Disponible en: https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-institute-deafness-other communication-disorders-nidcd
Prenzler NK, Bültmann E, Giourgas A, Steffens M, Salcher RB, Stolle S, et al. Cochlear implantation in patients with definite Meniere’s disease. Eur Arch Otorhinolaryngol. 2017;274(2):751-756. doi: 10.1007/s00405-016-4356-z
Lustig LR, Yeagle J, Niparko JK, Minor LB. Cochlear implantation in patients with bilateral Ménière’s syndrome. Otol Neurotol. 2003;24(3):397-403. doi: 10.1097/00129492-200305000-00009
American Academy of Pediatrics Steering Committee on Quality Improvement and Management (2004). Classifying recommendations for clinical practice guidelines. Pediatrics, 114(3), 874–877. https://doi.org/10.1542/peds.2004-1260
Tomado de Anon (2018). Directriz para el fortalecimiento de los programas nacionales de guías informadas por la evidencia. Una herramienta para la adaptación e implementación de guías en las Américas. (https://iris.paho.org/handle/10665.2/49145